Affinity Asset Advisors’s Axsome Therapeutics AXSM Stock Holding History

Affinity Asset Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,000	Closed	-$5.22M	–	100
2025 Q2	$5.22M	Sell	50,000 -50,000	-50%	-$5.29M	0.71%	39
2025 Q1	$11.7M	Buy	100,000 +25,000	+33%	+$2.85M	1.11%	22
2024 Q4	$6.35M	Sell	75,000 -5,000	-6%	-$460K	0.85%	31
2024 Q3	$7.19M	Hold	80,000	–	–	0.98%	33
2024 Q2	$6.44M	Sell	80,000 -59,758	-43%	-$4.42M	0.74%	37
2024 Q1	$11.2M	Buy	139,758 +89,758	+180%	+$7.53M	1.38%	23
2023 Q4	$3.98M	Buy	+50,000	New	+$3.34M	0.73%	39
2023 Q3	–	Sell	-12,500	Closed	-$898K	–	82
2023 Q2	$898K	Buy	+12,500	New	+$922K	0.31%	55
2021 Q3	–	Sell	-25,000	Closed	-$1.69M	–	77
2021 Q2	$1.69M	Buy	25,000 +15,000	+150%	+$900K	0.6%	38
2021 Q1	$566K	Hold	10,000	–	–	0.19%	63
2020 Q4	$815K	Buy	+10,000	New	+$748K	0.43%	47

Other funds holding AXSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Affinity Asset Advisors's AXSM Position: Q3 2025 in Review

Affinity Asset Advisors sold out of Axsome Therapeutics (AXSM) in Q3 2025, closing a stake of 50,000 shares — an estimated $5.22M sold.

Affinity Asset Advisors first reported a position in AXSM in Q4 2020 and held it in 11 quarters. The position peaked at $11.7M in Q1 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

Affinity Asset Advisors reported no remaining Axsome Therapeutics position as of Q3 2025 after selling out during the quarter.
Affinity Asset Advisors sold 50,000 Axsome Therapeutics shares in Q3 2025, an estimated $5.22M.
Affinity Asset Advisors first reported a position in Axsome Therapeutics in Q4 2020 and held it in 11 quarters.
Affinity Asset Advisors's Axsome Therapeutics position peaked at $11.7M in Q1 2025.
355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.